PremiumCompany AnnouncementsVaxxinity Faces Nasdaq Delisting Over Share Price Vaxxinity announces publication of data on VXX-401 Vaxxinity announces research collaboration with CTRND PremiumThe FlyVaxxinity announces publication of Phase 2 trial of UB-311 Vaxxinity reports Q2 EPS (11c) vs (14c) last year Vaxxinity announces new Phase 1 trial data for UB-312 PremiumThe FlyVaxxinity announces first subjects dosed in Phase 1 trial of VXX-401 Vaxxinity announces Phase 3 COVID-19 booster data for UB-612 Vaxxinity to hold analyst and research and development day 
